A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease

This study has been completed.
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
First received: November 2, 1999
Last updated: August 26, 2010
Last verified: November 2005

Lyme disease is the most common tick-borne disease in the United States. It is caused by the spirochete Borrelia burgdorferi. It may exist in a chronic form and be the result of: 1) persistent infection by B. burgdorferi; 2) damage caused by the original infectious process; or 3) the presence of coinfection with another organism transmitted by Ixodes ticks. The purpose of this study is to determine the safety and effectiveness, in seronegative patients, of intensive antibiotic treatment in eliminating symptoms of Chronic Lyme Disease (CLD).

Condition Intervention Phase
Lyme Disease
Drug: ceftriaxone
Drug: doxycycline
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease

Resource links provided by NLM:

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 66
Estimated Study Completion Date: November 2005
Detailed Description:

Sixty-six patients will be enrolled in this study. Each patient will be assigned to one of two groups and will be randomly selected to receive either antibiotic therapy or placebo; but, the assignment of medication will not be made known to the patient or administering doctor. Antibiotic or placebo will be given intravenously (IV) for 30 consecutive days and then orally for the next 60 consecutive days.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

You may be eligible for this study if you:

  • Are at least 18 years of age.
  • Are seronegative for antibodies against B. burgdorferi antigens by Western Blot at enrollment.
  • Have documented history of acute Lyme disease.
  • Have had a rash (erythema migrans) that resembles a bullseye. This skin aberration usually occurs after a tick bite in late spring, summer, or early fall and is sometimes accompanied by fatigue, fever, headache, mild stiff neck, arthralgia or myalgia.
  • Have had one or more clinical features typical of Lyme disease acquired in the United States (see technical summary)
  • Have had one or more of the following symptoms and conditions that have persisted for at least 6 months (but less than 12 years) and are not attributable to another cause or condition: a) widespread musculoskeletal pain and fatigue that began coincident with or within 6 months following initial infection with B. burgdorferi. b) certain neurologic symptoms including memory impairment and nerve pain, beginning within 6 months following initial infection with B. burgdorferi.
  • Have had a physician-documented history of prior antibiotic treatment with a currently recommended antibiotic regimen.

Exclusion Criteria:

You will not be eligible for this study if you:

  • Have previously enrolled in this study.
  • Are pregnant, lactating, or unable to use birth control measures during the treatment period of this study.
  • Are taking chronic medication that could interfere with evaluation of symptoms.
  • Are taking or have taken various medications that could interfere with the evaluation of symptoms (see technical summary).
  • Are hypersensitive to ceftriaxone or doxycycline.
  • Have active inflammatory synovitis.
  • Have another disease that could account for symptoms of acute Lyme disease.
  • Have another serious or active infection.
  • Are unable to tolerate an IV.
  • Have tested positive for Borrelia DNA in plasma or cerebrospinal fluid at the time of initial evaluation for study.
  • Have tested seropositive by Western Blot (these patients may be offered enrollment in seropositive study).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000938

United States, Massachusetts
Mark Klempner
Boston, Massachusetts, United States, 02111
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000938     History of Changes
Other Study ID Numbers: DMID 97-003
Study First Received: November 2, 1999
Last Updated: August 26, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Lyme Disease
Borrelia Infections
Tick-Borne Diseases
Bacterial Infections
Gram-Negative Bacterial Infections
Spirochaetales Infections
Anti-Bacterial Agents
Anti-Infective Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on August 27, 2015